여성 건강 치료제 시장 기회와 촉진요인, 산업 동향 분석 및 예측(2025-2034년)

The Global Womens Health Therapeutics Market was valued at USD 44.6 billion in 2024 and is estimated to grow at a CAGR of 4.7% to reach USD 69.5 billion by 2034.

Conditions like endometriosis, menopause-related issues, polycystic ovary syndrome (PCOS), and osteoporosis is increasingly common. This growing disease burden is pushing demand for more effective and targeted therapeutics.

Increasing Adoption of Hormonal Therapies

The hormonal therapies segment held a significant share in 2024, driven by the rising demand for treatments that address conditions such as menopause symptoms, endometriosis, and hormonal imbalances. As awareness grows around hormone replacement therapy (HRT) and the long-term health impacts of untreated hormonal issues, more women are seeking medical intervention. The market has seen continuous innovation in delivery mechanisms, including patches, gels, and sustained-release implants, which enhance patient compliance.

Rising Prevalence of Contraception

The contraception segment generated a sizeable share in 2024, driven by rising demand for both long-acting reversible contraceptives (LARCs) and non-hormonal options. Modern lifestyles, delayed family planning, and growing public health support for reproductive autonomy have fueled adoption across a broad demographic. The market is evolving beyond traditional oral contraceptives, with innovations in vaginal rings, intrauterine devices (IUDs), and injectable formats.

Prescription to Gain Traction

The prescription segment held a substantial share in 2024, owing to the clinical nature of most treatments for conditions like osteoporosis, fertility issues, and gynecological cancers. Physicians remain key decision-makers, and patient trust in prescribed medications continues to drive brand loyalty. Regulatory approval pathways, formulary positioning, and insurance coverage significantly impact sales performance in this segment.

North America to Emerge as a Propelling Region

North America womens health therapeutics market is poised to grow at a decent CAGR during 2025-2034. The region benefits from advanced healthcare infrastructure, strong regulatory oversight, and high awareness levels among both patients and providers. Market players are capitalizing on favorable reimbursement policies and rising demand for targeted treatments across various stages of a woman's life cycle, from adolescence to post-menopause.

Major players in the women's health therapeutics market are Theramex, Cipla, Kissei Pharmaceutical, Evofem, Pfizer, Shionogi, Ferring, Organon, Amgen, Besins, Allergan (AbbVie), Sanofi, Gedeon Richter, Lupin, Atossa Therapeutics, Novartis, Johnson & Johnson, and Bayer.

To strengthen their market foothold in the women's health therapeutics space, companies are focusing on a multi-pronged approach. Key strategies include expanding product pipelines through in-house R&D and licensing deals, particularly for underserved conditions such as uterine fibroids and female sexual dysfunction. Mergers and acquisitions are also being used to consolidate market presence and gain access to innovative technologies.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional
  • 2.2.2 Drug type
  • 2.2.3 Application
  • 2.2.4 Medication type
  • 2.2.5 Age group
  • 2.2.6 Distribution channel
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Value addition at each stage
  • 3.1.3 Factors affecting the value chain
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of chronic and lifestyle diseases
    • 3.2.1.2 Enhanced education and public health campaigns
    • 3.2.1.3 Growing advancement in personalized medicine
    • 3.2.1.4 Increasing demand for menstrual health and hygiene therapeutics
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Social stigma around menstruation, infertility, and menopause
    • 3.2.2.2 High treatment cost
    • 3.2.2.3 Regulatory challenges
  • 3.2.3 Market opportunities
    • 3.2.3.1 Expansion in emerging markets
    • 3.2.3.2 Growing focus on preventive women's healthcare
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Pipeline analysis
• 3.6 Investment and funding landscape in the women's health sector
• 3.7 Technological landscape
• 3.8 Future market trends
• 3.9 Porter’s analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Hormonal therapies
• 5.3 Pain and symptom management drugs
• 5.4 GnRH modulators
• 5.5 Bone health agents
• 5.6 Metabolic drugs
• 5.7 Fertility drugs
• 5.8 Other drug types

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Contraception
• 6.3 Menopause and post-menopausal management
• 6.4 Hormonal disorders
• 6.5 Endometriosis and uterine fibroids
• 6.6 Reproductive health and fertility care
• 6.7 Bone health and osteoporosis
• 6.8 Other applications

Chapter 7 Market Estimates and Forecast, By Medication Type, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Over the counter (OTC)
• 7.3 Prescription

Chapter 8 Market Estimates and Forecast, By Age Group, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Below 20
• 8.3 21-50
• 8.4 51 and above

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 Offline channels
  • 9.2.1 Hospital pharmacies
  • 9.2.2 Retail pharmacies
  • 9.2.3 Other offline stores
• 9.3 Online channels

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Italy
  • 10.3.5 Spain
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Allergan (AbbVie)
• 11.2 Amgen
• 11.3 Atossa Therapeutics
• 11.4 Bayer
• 11.5 Besins
• 11.6 Cipla
• 11.7 Evofem
• 11.8 Ferring
• 11.9 Gedeon Richter
• 11.10 Johnson & Johnson
• 11.11 Kissei Pharmaceutical
• 11.12 Lupin
• 11.13 Novartis
• 11.14 Organon
• 11.15 Pfizer
• 11.16 Sanofi
• 11.17 Shionogi
• 11.18 Theramex